Metabasis Therapeutics, Inc. (NASDAQ: MBRX), a biopharmaceutical company, focuses their efforts on discovering, developing and commercializing innovative drugs by applying its scientific expertise, proprietary technologies and unique capabilities for targeting the liver and liver pathways. The company has established advanced research programs and a broad pipeline of product candidates, all of which were developed through the leveraging of their proprietary technologies. For further information, visit the Company’s web site at www.mbasis.com.
- 17 years ago
QualityStocks
Metabasis Therapeutics, Inc. (NASDAQ: MBRX)
Tags Rodman & Renshaw
Related Post
-
Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Year-End Report Shows Alignment with Domestic Resource Priorities, Strong Strategic Positioning
Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include…
-
CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) to Execute Comprehensive Exploration Plan Focused on Promising Potential of Multiple Additional Silver-Bearing Veins
Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may…
-
Scaling Care, Tightening Controls: How Earth Science Tech Inc. (ETST) Is Building a Multi-Unit Healthcare Platform
Earth Science Tech reported fiscal Q3 2026 revenue of $8.4 million, up 14.1% year over…